U.S. markets closed
  • S&P Futures

    4,450.50
    +12.50 (+0.28%)
     
  • Dow Futures

    34,726.00
    +82.00 (+0.24%)
     
  • Nasdaq Futures

    15,329.50
    +26.00 (+0.17%)
     
  • Russell 2000 Futures

    2,263.20
    +8.00 (+0.35%)
     
  • Crude Oil

    73.28
    -0.02 (-0.03%)
     
  • Gold

    1,747.20
    -2.60 (-0.15%)
     
  • Silver

    22.59
    -0.09 (-0.39%)
     
  • EUR/USD

    1.1748
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.4100
    +0.0740 (+5.54%)
     
  • Vix

    18.63
    -2.24 (-10.73%)
     
  • GBP/USD

    1.3734
    +0.0014 (+0.10%)
     
  • USD/JPY

    110.3930
    +0.0920 (+0.08%)
     
  • BTC-USD

    44,758.61
    +1,274.02 (+2.93%)
     
  • CMC Crypto 200

    1,121.81
    +12.89 (+1.16%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    30,214.74
    +575.34 (+1.94%)
     

Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2021, on Monday, May 10, 2021 before the opening of the financial markets.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

Akebia will host a conference call at 9:00 a.m. Eastern Time on Monday, May 10, to discuss its first quarter financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 6250159. The call will also be webcast LIVE and can be accessed via the Investors section of the Company's website at http://ir.akebia.com.

A replay of the conference call will be available two hours after the completion of the call through May 16, 2021. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 6250159. An online archive of the conference call can be accessed via the Investors section of the Company's website at http://ir.akebia.com.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Investor Contact
Kristen K. Sheppard, Esq
ir@akebia.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-first-quarter-2021-financial-results-and-discuss-recent-business-highlights-301278435.html

SOURCE Akebia Therapeutics